NICE Draft Guidance Recommends Astellas’ Xtandi for Prostate Cancer

Regulatory body, the National Institute for Health and Care Excellence (NICE), have opened a second consultation on the use of Astellas’ Xtandi in patients with prostate cancer, after widening the drug’s target population. The regulatory affairs agency issued new draft guidance this morning recommending the use of Xtandi in adult patients with hormone relapsed metastatic

Continue Reading

Dificlir Gains European Approval

Astellas and partner Optimer Pharmaceuticals announced yesterday that regulators in Europe have given the green light to their antibiotic Dificlir. The European Commission has approved Dificlir (fidaxomicin) for the treatment of Clostridium Difficile infections (CDI) in adults, which can cause severe diarrhoea. The approval is based on two Phase III trials which compared Dificlir with

Continue Reading